Targeting gastrointestinal microbiota as new diagnostic and treatment options in Depression

Detalhes bibliográficos
Autor(a) principal: Ana Sofia Parente Meixedo
Data de Publicação: 2020
Tipo de documento: Dissertação
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://hdl.handle.net/10216/128849
Resumo: Background/Objective: Depression has been increasingly recognized as a prevalent public health problem. In order to improve the disease's diagnostic and treatment options, the genetic and environmental factors that contribute to depression pathogenesis must be further understood - a factor recently considered to be heavily influential is the composition of the intestinal microbiome. This narrative review aims to expose the current state of knowledge on the relationship between Gastrointestinal Microbiome and Depression and to outline the existing scientific evidence about the effects of probiotics, prebiotics and antibiotics supplementation in depression. Methods: Using PubMed as the database, a research was conducted targeting articles written in English about how Gastrointestinal Microbiome relates with Depression. Results: The gastrointestinal microbiome is capable of affecting the neuronal function through neurotransmitters, vitamins and neuroactive metabolites via the microbiota-gut-brain axis. Recent studies have pointed out a noticeable difference in the intestinal microbiota composition of patients with depressive disorder. Additionally, clinical trials have demonstrated that the supplementation of probiotics containing specific bacteria may influence the body's response to stress and may regulate some depressive and anxiety symptoms in humans. However, some studies do not support this evidence, stating that probiotics do not influence psychiatric pathology in any way. Conclusion: Targeting microbiota composition as a diagnostic and treatment option in depression is an appealing possibility, however the knowledge available today is not enough to apply these principles with certainty in clinical practice. Future studies are necessary for it to become a fully approved reality in psychiatry.
id RCAP_38c6214469e3c3859bf767c8ba501efd
oai_identifier_str oai:repositorio-aberto.up.pt:10216/128849
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Targeting gastrointestinal microbiota as new diagnostic and treatment options in DepressionCiências médicas e da saúdeMedical and Health sciencesBackground/Objective: Depression has been increasingly recognized as a prevalent public health problem. In order to improve the disease's diagnostic and treatment options, the genetic and environmental factors that contribute to depression pathogenesis must be further understood - a factor recently considered to be heavily influential is the composition of the intestinal microbiome. This narrative review aims to expose the current state of knowledge on the relationship between Gastrointestinal Microbiome and Depression and to outline the existing scientific evidence about the effects of probiotics, prebiotics and antibiotics supplementation in depression. Methods: Using PubMed as the database, a research was conducted targeting articles written in English about how Gastrointestinal Microbiome relates with Depression. Results: The gastrointestinal microbiome is capable of affecting the neuronal function through neurotransmitters, vitamins and neuroactive metabolites via the microbiota-gut-brain axis. Recent studies have pointed out a noticeable difference in the intestinal microbiota composition of patients with depressive disorder. Additionally, clinical trials have demonstrated that the supplementation of probiotics containing specific bacteria may influence the body's response to stress and may regulate some depressive and anxiety symptoms in humans. However, some studies do not support this evidence, stating that probiotics do not influence psychiatric pathology in any way. Conclusion: Targeting microbiota composition as a diagnostic and treatment option in depression is an appealing possibility, however the knowledge available today is not enough to apply these principles with certainty in clinical practice. Future studies are necessary for it to become a fully approved reality in psychiatry.2020-05-222020-05-22T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisapplication/pdfhttps://hdl.handle.net/10216/128849TID:202612635engAna Sofia Parente Meixedoinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-29T13:36:32Zoai:repositorio-aberto.up.pt:10216/128849Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T23:43:42.842293Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Targeting gastrointestinal microbiota as new diagnostic and treatment options in Depression
title Targeting gastrointestinal microbiota as new diagnostic and treatment options in Depression
spellingShingle Targeting gastrointestinal microbiota as new diagnostic and treatment options in Depression
Ana Sofia Parente Meixedo
Ciências médicas e da saúde
Medical and Health sciences
title_short Targeting gastrointestinal microbiota as new diagnostic and treatment options in Depression
title_full Targeting gastrointestinal microbiota as new diagnostic and treatment options in Depression
title_fullStr Targeting gastrointestinal microbiota as new diagnostic and treatment options in Depression
title_full_unstemmed Targeting gastrointestinal microbiota as new diagnostic and treatment options in Depression
title_sort Targeting gastrointestinal microbiota as new diagnostic and treatment options in Depression
author Ana Sofia Parente Meixedo
author_facet Ana Sofia Parente Meixedo
author_role author
dc.contributor.author.fl_str_mv Ana Sofia Parente Meixedo
dc.subject.por.fl_str_mv Ciências médicas e da saúde
Medical and Health sciences
topic Ciências médicas e da saúde
Medical and Health sciences
description Background/Objective: Depression has been increasingly recognized as a prevalent public health problem. In order to improve the disease's diagnostic and treatment options, the genetic and environmental factors that contribute to depression pathogenesis must be further understood - a factor recently considered to be heavily influential is the composition of the intestinal microbiome. This narrative review aims to expose the current state of knowledge on the relationship between Gastrointestinal Microbiome and Depression and to outline the existing scientific evidence about the effects of probiotics, prebiotics and antibiotics supplementation in depression. Methods: Using PubMed as the database, a research was conducted targeting articles written in English about how Gastrointestinal Microbiome relates with Depression. Results: The gastrointestinal microbiome is capable of affecting the neuronal function through neurotransmitters, vitamins and neuroactive metabolites via the microbiota-gut-brain axis. Recent studies have pointed out a noticeable difference in the intestinal microbiota composition of patients with depressive disorder. Additionally, clinical trials have demonstrated that the supplementation of probiotics containing specific bacteria may influence the body's response to stress and may regulate some depressive and anxiety symptoms in humans. However, some studies do not support this evidence, stating that probiotics do not influence psychiatric pathology in any way. Conclusion: Targeting microbiota composition as a diagnostic and treatment option in depression is an appealing possibility, however the knowledge available today is not enough to apply these principles with certainty in clinical practice. Future studies are necessary for it to become a fully approved reality in psychiatry.
publishDate 2020
dc.date.none.fl_str_mv 2020-05-22
2020-05-22T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
format masterThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://hdl.handle.net/10216/128849
TID:202612635
url https://hdl.handle.net/10216/128849
identifier_str_mv TID:202612635
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799135752455454720